Blog · Evidence, in plain language
When your patient is offered CBT-I and a sleep medicine together.
Patients with chronic insomnia often arrive in therapy already taking a sleep medicine, or they ask in session whether adding one to CBT-I would speed things up. In 2026 the American Academy of Sleep Medicine published a guideline that compared starting both treatments at once against starting either one alone. This post sets out its ranking, the thin evidence under it, and which parts of the question sit in your room and which sit with the prescriber.
By Karel Winner, DNP, PMHNP-BC · Published October 13, 2026
This post is professional education, not clinical guidance for an individual patient. It summarizes a published guideline. Medication decisions belong to the patient and the prescriber.
What the guideline found
Chronic insomnia disorder affects roughly 10 to 15 percent of adults. The guideline defines combination treatment as CBT-I started at the same time as insomnia medication, and its two recommendations form a ranking. CBT-I alone is placed first. The combination is suggested over medication alone, because it improved overall insomnia severity and sleep continuity by amounts the panel judged clinically meaningful. The combination is suggested against over CBT-I alone, because it added no meaningful gain in severity, continuity, or daytime symptoms for most patients. Both recommendations are conditional, and the panel rated the certainty of the evidence as low.
The base under that ranking is small. Each comparison drew on six randomized trials reported in seven articles, drawn from a literature search completed in June 2025. Against medication alone, the combination group reported slightly more morning sleepiness, judged a minimal effect. Against CBT-I alone, the combination did raise total sleep time by an amount the panel counted as meaningful, although the confidence interval included zero. The panel also wrote an exception into the guideline: a patient who values more total sleep early in treatment, or cares less about daytime symptom relief, may reasonably choose the combination. Sequential care, adding a second treatment later when the first falls short, was barely studied and received no recommendation.
What belongs in the therapy room
CBT-I itself is therapy work, and the 2021 AASM guideline on behavioral treatments gave its multicomponent form a strong recommendation, the only strong rating in this area. The skills a patient practices, the sleep schedule they hold, and the thoughts about sleep they bring to session are the material of your room, whether you deliver CBT-I yourself or support a patient doing it elsewhere. Adherence questions are also yours to explore: a patient who quietly stops the behavioral program while keeping the medicine has, on this evidence, kept the weaker half, and that pattern is worth naming in session.
Daytime symptoms are session material too. The guideline found daytime improvement no better, and possibly a little smaller, when medication was added to CBT-I. A patient who sleeps somewhat longer but feels groggier in the morning or flatter in the day is reporting exactly the trade-off the panel weighed. Helping the patient describe that change clearly, when it started, and how it tracks with the medicine gives the prescriber information no sleep diary holds.
What belongs to the prescriber
Whether a medicine is started, kept, changed, or stopped is a prescribing decision. It turns on the patient's diagnosis, other conditions such as sleep apnea or depression, the full medication list, and past response, none of which a therapist should have to weigh in session. The same holds for morning sleepiness that affects driving or a safety sensitive job: the report should reach the prescriber promptly, not wait for a routine visit. Your part is the routing and the observation. Noticing the pattern, asking the patient to report it in specific terms, and supporting the behavioral program in the meantime is the work therapy does well here, and it is the work this guideline's ranking depends on.
Sources
Buysse and colleagues, Journal of Clinical Sleep Medicine (2026): the American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults, with the evidence search completed in June 2025. Journal of Clinical Sleep Medicine.
American Academy of Sleep Medicine (2026): the guideline at a glance summary, listing both recommendations and the exception for patients who value more total sleep early in treatment. AASM guideline at a glance.
Edinger and colleagues, Journal of Clinical Sleep Medicine (2021): the earlier AASM guideline on behavioral and psychological treatments for chronic insomnia, which gave multicomponent CBT-I its strong recommendation. PubMed record.
If a patient is having thoughts of harming themselves, the crisis standard applies: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service.